Sunovion announced the upcoming availability of Zetonna (ciclesonide) nasal aerosol indicated for the treatment of both ocular and nasal symptoms associated with seasonal allergic rhinitis (SAR), and the treatment of nasal symptoms associated with perennial allergic rhinitis (PAR) in adults and adolescents aged >12 years. Zetonna was approved by the FDA in January 2012.
Zetonna is the only non-aqueous, dry nasal aerosol spray with one spray per nostril (37mcg) and once-daily dosing. It features an easy-to-read, built-in dose indicator so patients can track when their prescriptions should be refilled.
Zetonna contains the same active ingredient found in Sunovion’s Omnaris nasal spray, a hypotonic formulation indicated for the treatment of SAR and PAR, and Alvesco inhalation aerosol, indicated for the maintenance treatment of asthma. Zetonna will be commercially available in the US starting in the third quarter of 2012.
For more information call (800) 739-0565 or visit www.sunovion.com.